Trial Profile

Safety and Immunogenicity of a Shigella tetravalent bioconjugate vaccine in adults

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 07 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GSK 4069327A (Primary) ; Aluminium hydroxide
Indications Shigella infections
Focus Adverse reactions; Pharmacodynamics
Acronyms SIS4V study
Sponsors LimmaTech Biologics

Most Recent Events

01 Mar 2024 Status changed from not yet recruiting to discontinued.
02 Oct 2023 Planned initiation date changed from 9 Oct 2023 to 1 Mar 2024.
08 Sep 2023 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com